Time-dependent variations in bone turnover parameters during 2 months' cyclic treatment with different doses of combined estrogen and progestogen in postmenopausal women.
We determined the time-dependent variations in biochemical estimates of bone resorption and bone formation in 30 healthy postmenopausal women treated for two consecutive cycles of 28 days with a sequential estrogen/gestagen therapy. The women received either 1, 2, or 4 mg estradiol (E2) for 22 days and 1 mg norethisterone acetate (NETA) from day 13 to 22 of each cycle. Blood samples were drawn twice a week, ie, 16 blood samples in each woman. Biochemical estimates of bone resorption (fasting urinary hydroxyproline/creatinine, fasting urinary calcium/creatinine) decreased significantly during the two treatment cycles. In contrast, there was no overall decrease in bone formation parameters (plasma bone Gla protein [pBGP], serum alkaline phosphatase), and serum alkaline phosphatase decreased significantly during the estrogen-only phase, but increased during the E2 plus NETA phase. The present study supports our previous suggestion that NETA stimulates bone formation in early postmenopausal women.
Johansen
J S
JS
Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen, Denmark.
Jensen
S B
SB
Riis
B J
BJ
Christiansen
C
C
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004958:Estradiol / Q000627:therapeutic use*; D004971:Estrus; D005260:Female; D006801:Humans; D008593:Menopause / Q000378:metabolism; D008875:Middle Aged; D009640:Norethindrone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077563:Norethindrone Acetate; D015675:Osteocalcin / Q000097:blood; D010012:Osteogenesis; D013997:Time Factors
D004338:Drug Combinations; D015675:Osteocalcin; D004958:Estradiol; D000077563:Norethindrone Acetate; D002118:Calcium; D009640:Norethindrone